Abstract
In schizophrenia, genetic and environmental factors affect neurodevelopment and neuroprogressive trajectory. Altered expression of neuro-immune genes and increased levels of cytokines are observed, especially in patients with comorbid depression. However, it remains unclear whether circulating levels of cytokines and expression of these genes are associated, and how antipsychotic treatments impact this association. Relationships between messenger RNA (mRNA) expression of 11 schizophrenia-related genes and circulating levels of cytokines (interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-α) were analyzed in 174 antipsychotic naïve first episode psychosis (FEP) and in 77 healthy controls. A subgroup of 72 patients was reassessed after treatment with risperidone. FEP patients were divided into those with and without depression. FEP patients with depression showed increased COMT expression and decreased NDEL1 expression. Increased IL-6 was associated with lowered AKT1 and DROSHA expression, while increased IL-10 was associated with increased NDEL1, DISC1, and MBP expression. IL-6 levels significantly increased the risperidone-induced expression of AKT1, DICER1, DROSHA, and COMT mRNA. The differential mRNA gene expression in FEP is largely associated with increased cytokine levels. While increased IL-6 may downregulate AKT-mediated cellular functions and dysregulate genes involved in microRNA (miRNA) machinery, increased IL-10 has neuroprotective properties. Increased IL-6 levels may prime the expression of genes (AKT1, DICER1, DROSHA, and COMT) in response to risperidone, suggesting that cytokine × treatment × gene interactions may improve cell function profiles. FEP patients with depression show a different gene expression profile reinforcing the theory that depression in FEP is a different phenotype.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Schizophrenia is a complex mental disorder, one of the leading causes of disease burden in the world, notably in young adults [1]. Its phenotype is highly heterogeneous, possibly due to different clinical subgroups [2] and staging characteristics [3]. It has an important genetic component, with a high heritability, estimated at up to 80 % [4], in which common genetic variants with a small effect and/or rare genetic variants with a large effect interact with environmental factors [5]. Immune-inflammatory processes are involved in disorder onset and progression of schizophrenia and are associated with both genetic and environmental risk factors [6, 7].
Different pathological processes triggered by multiple hits, such as infections or psychosocial trauma, play a role in the pathophysiology of schizophrenia. These pathways include the dopaminergic system, immune-inflammatory and neuroprogressive pathways, neurodevelopmental processes, messenger RNA (mRNA) degradation or translational inhibition as well as epigenetic factors [3, 7]. The largest genome-wide association studies (GWASs) have consistently provided support for a link between the immune system, neuroprogression, and schizophrenia [6, 8]. These pathways contribute to the pathophysiology of schizophrenia, and their interaction may explain the multiple triggers that induce the disorder [7, 9].
Many different immune abnormalities are found in schizophrenia, including increased levels of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α, and the negative immune regulatory cytokine IL-10 [10]. IL-6 and TNF-α are involved in both neurodevelopmental and neuroprogressive processes and may cause dysfunctions in neuroplasticity and neurogenesis, including growth, differentiation, myelination, apoptosis, synaptic branching, and neurotrophin regulation [11, 12]. They also activate neurotransmitter signaling, e.g., catecholamines [13]. IL-10, on the other hand, has anti-inflammatory properties, while negatively modulating the immune response and having neuroprotective effects [14].
Increased levels of pro-inflammatory cytokines regulate gene expression and protein synthesis. For example, the administration of pro-inflammatory cytokines or lipopolysaccharide (LPS) provokes a significant reduction of BDNF expression [15]. The activities of pro-inflammatory cytokines also activate nuclear factor-κB, a transcription factor, responsible for the regulation of several genes, including cytokines [16, 17]. Moreover, IL-6 may mediate epigenetic alterations in cells via the regulation of the DNA methyltransferase enzyme gene (DNMT-1) [18], which has also been implicated in schizophrenia [19, 20].
Complex effects of antipsychotic drugs on the immuno-inflammatory, oxidative stress, and neuroprogressive pathways have been described showing that these drugs may modulate immune and oxidative pathways, synaptic plasticity, and myelin generation [7, 21, 22]. Risperidone treatment has immunoregulatory effects on drug naïve first episode psychosis (FEP) patients [21] and may regulate mRNA expression of GABRR2 and GCH1 [23–25].
Clinical variables may contribute to the regulation of genetic and immune pathways. Depression is a prevalent comorbidity in schizophrenia [26], reaching up to 80 % in FEP patients [27]. Patients with concomitant depressive symptoms have more dysfunctions in immune-inflammatory pathways [28]. In this study, we selected 11 targeted genes in schizophrenia (AKT1, DICER1, NDEL1, TNF, UFD1L, DROSHA, COMT, DISC1, MBP, IL2, and IL6) and analyzed their expression in FEP patients in relation to depression and circulating levels of cytokines both before and after treatment with risperidone. Genes selection was based on their function as follows: dopamine neurotransmission (COMT); inflammation and immune system (TNF, IL2, and IL6); neurodevelopment (DISC1 and NDEL1); myelination (MBP); cell signaling (AKT1); microRNA machinery (DICER1 and DROSHA); and degradation of proteins (UFD1L); and based on their mRNA expression previously described in whole blood (according to information available in http://www.genecards.org/).
Subjects and Methods
The present study is part of a prospective cohort study performed in Sao Paulo, Brazil, which examines different characteristics of antipsychotic naïve FEP patients, including gene expression and their immune-inflammatory profile. Patients were followed during the treatment with risperidone for delineating the effects of this antipsychotic. All participants provided written informed consent prior to enrollment in this study. The study was approved by the Research Ethics Committee of UNIFESP (Sao Paulo, Brazil) and carried out in accordance with the Declaration of Helsinki.
Study Population
Antipsychotic-naïve FEP patients (N = 174) were recruited from a psychiatric emergency unit in São Paulo, Brazil. The diagnosis of a psychotic disorder was established by trained psychiatrists, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), using the Structured Clinical Interview of the DSM-IV (SCID-I). Only individuals between 16 and 40 years of age with no prior history of antipsychotic medication exposure were selected. Individuals with psychotic episodes due to a general medical condition, substance-induced psychotic disorder, or intellectual disability were excluded. All patients fulfilled the criteria for one of the following diagnoses: schizophrenia (53.2 %), schizophreniform disorders (17.4 %), brief psychotic disorders (12.0 %), psychotic disorders not otherwise specified (10.9 %), and manic episode with psychotic symptoms (6.5 %). None of the patients had previously received any psychiatric diagnosis. The comparison group consisted of 77 healthy volunteers. Controls and their first-degree family members had a negative lifetime history of major psychiatric disorder, according to the criteria of the DSM-IV. We excluded patients and controls with acute and chronic medical conditions associated with an imbalance in the immune system, including infections (e.g., HIV), allergic reactions, pregnancy, the postpartum period, rheumatic disorders, and using medications with immunomodulatory effects such as nonsteroidal anti-inflammatory drugs, corticosteroids, and immunosuppressants.
All patients received risperidone as standard treatment, with mean dose of 4.0 mg/day (SD = 2.1). A subgroup of 72 patients treated with risperidone was followed for 64 days (q25 = 56, q75 = 78) and reassessed after this period. All patients were evaluated using the (a) PANSS (Positive and Negative Syndrome Scale) [29] and (b) CDSS (Calgary Depression Scale for Schizophrenia) [30]. In the subgroup that had a follow-up after treatment, the patients underwent interviews by the same experienced psychiatrist.
Analyses
A total of 15 mL of whole blood was collected in PAXgene® RNA (PreAnalytix, Hombrechtikon, Switzerland) and SST tubes (Becton Dickinson, Plymouth, UK), and from all patients at admission, before the first dose of risperidone, and after treatment, and from 77 healthy controls after the SCID-I interview. Blood was centrifuged and RNA was isolated using a PAXgene® Blood RNA kit (Qiagen, Germantown, MD) according to the manufacturer’s instructions. The serum was stored at −80 °C until thawed for assays of cytokines.
mRNA Expression
The RNA integrity was determined through electrophoresis on a 1.0 % agarose gel, and the quality and quantity of the RNA samples were determined using a NanoDrop® ND-1000 spectrophotometer (Nanodrop, Wilmington, DE). Approximately 400 ng of each RNA sample was reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Foster City, CA), and 20–100 ng were diluted in H2O, mixed with TaqMan® Universal PCR Master Mix (Life Technologies) and loaded on the Taqman Low-Density Array (TLDA) microfluidic cards (Life Technologies). Probes and primers of 11 target genes and two housekeeping genes (HKGs: ACTB and GAPDH) were preloaded in the 384 wells of each TLDA card (Life Technologies), and the experiments were performed in accordance with the manufacturer’s instructions using the ViiA™ 7 Real-Time PCR System (Life Technologies). Assays and exons and transcripts that they recognize are described in Supplementary Table 1. Gene expression was quantified using the relative threshold method (Crt) with the geometric mean (GM) between ACTB and GAPDH as the endogenous control. ΔCrt values (ΔCrt = Crt target gene − CrtGM) were calculated for each sample and included in the SPSS (version 19.0) dataset. There is an inverse correlation between ΔCrt and gene expression. Gene expression data were measured in 72 patients and 73 controls. Power analysis showed that for the primary outcome data (mRNA gene expression), the sample size should be around 140 when considering 2 groups, an effect size of 0.24, α = 0.05, and power = 0.8.
Cytokines
Serum IL-6, IL-10, and TNF-α were measured by flow cytometry using the Cytometric Bead Array Human Th1/Th2/Th17 Kit (BD Biosciences). Acquisition was performed with a FACS Canto II flow cytometer (BD Biosciences). The instrument was checked for sensitivity and overall performance with Cytometer Setup and Tracking beads (BD Biosciences) prior to data acquisition. Quantitative results were generated using FCAP Array v1.0.1 software (Soft Flow Inc.). The cytokine data were entered as continuous variables (in Ln transformation) and as groups that is lower versus higher concentration levels, i.e., using cutoff values of IL-6 2.2 pg/mL; TNF-α 1.5 pg/mL and IL-10 1.3 pg/mL. Cytokines were measured in 157 patients and in 58 controls.
Statistical Analyses
We used analysis of contingency tables (χ 2 test) or simple analysis of variance to assess the associations between diagnosis and clinical and sociodemographic data. Multiple post-hoc differences among treatment means were examined using protected Bonferroni-corrected comparisons. Automatic binary logistic regression analysis was employed to delineate the significant gene expression predictors of the FEP group. Multivariate and univariate general linear model (GLM) analyses were used to assess the associations between the gene expression data (dependent variables) and explanatory variables, including diagnosis, age, gender, and sociodemographic data. Regression analysis was used to examine the relationships between gene expression data (dependent variable) and explanatory variables, including IL-6 levels. Repeated measurements (RM) design GLM analyses were used to assess within-subject effects, i.e., time (treatment with risperidone) and the interaction time × group (e.g., diagnosis or IL-6 groups). The Levene test was used to test for homogeneity of variance. All tests were two-tailed and a p value of 0.05 was used for statistical significance.
Results
Table 1 shows the demographic and biomarker data of the subjects in this study. There were no significant differences in age or gender ratio between cases and controls. FEP subjects had a significantly lower personal and familial income than the controls. There were significantly more smokers in FEP patients than in controls. Therefore, we adjusted our results for these differences in these sociodemographic data.
The mRNA expression data for IL-2 and IL-6 were not detectable in many subjects, and therefore, these two cytokine expression data could not be included in the computations. Among the 72 FEP and 73 controls, DICER1 mRNA was measurable in all subjects, and mRNA expression of AKT1 (n = 1), COMT (n = 3), DROSHA (n = 9), NDEL1 (n = 1), TNF (n = 12), and UFD1L (n = 1) was not measurable in few subjects. There were no significant differences in the number of undetectable mRNA expression data between controls and patients for any of these genes.
The multivariate GLM analysis showed a significant effect of diagnosis (FEP patients versus controls) on the ΔCrt values of the nine genes (F = 2.68, df = 9/51, p = 0.012). Forced entry of age, gender, and smoking status showed that these variables were not associated with the gene expression data and that the effects of diagnosis remained significant. Consequently, we have performed between-subject and univariate GLM analyses on each of the genes separately because the number of subjects with detectable mRNA levels differs between the nine genes included in this study (thus lowering the degrees of freedom due to an increased number of missing values when the genes are combined in multivariate analyses). There were significant differences in NDEL1, DROSHA, COMT, DISC1, and MBP ΔCrt values between FEP patients and controls. There were also significant differences in serum levels of IL-10, IL-6, and TNF-α between both study groups.
Table 2 shows the results of two binary logistic regression analyses with the FEP diagnosis as dependent variable (healthy controls as reference group) and the significant variables (see Table 1), i.e., NDEL1, DROSHA, COMT, DISC1, and MBP with or without cytokines (IL-6, IL-10, and TNF-α), as explanatory variables. We found that the NDEL1 (negatively) and DISC1 (positively) ΔCrt values were significantly associated with the diagnosis of FEP (χ 2 = 12.36, df = 2, p = 0.002). Of all patients, 69.0 % were correctly classified with a sensitivity of 53.3 % and specificity of 81.8 % (Nagelkerke = 0.156). We also found that the DROSHA ΔCrt values, IL-6, and TNF-α groups were significantly positively associated with the diagnosis of FEP (χ 2 = 22.24, df = 3, p < 0.001). 73.5 % of all patients were correctly classified with a sensitivity of 63.3 % and specificity of 83.7 % (Nagelkerke = 0.271).
Table 3 shows the results of automatic univariate GLM analyses with the gene expression data as dependent variables and diagnosis (FEP patients versus controls) and cytokine groups as explanatory variables. AKT1 expression was significantly related to IL-6 groups. Diagnosis and IL-10 groups were significant predictors of NDEL1 and DISC1 expression. DROSHA was significantly related to the diagnosis and IL-6 groups. COMT expression was predicted by the diagnosis, and MBP was associated with IL-10 and TNF-α groups.
Table 4 shows the results of univariate GLM analyses with diagnostic groups, i.e., controls versus FEP patients with and without depression, as explanatory variables, and the genes that were significant in Table 1 as dependent variables. There were significant differences in NDEL1, DROSHA, COMT, and MBP, but not DISC1, between the three groups. There were additional differences in NDEL1 and COMT expression between patients with and without depression.
Table 5 shows the results of repeated measurement GLM analysis performed on the pre- and post-treatment gene expression data and considering the interaction time × IL-6 groups. We found significant time × IL-6 group interaction patterns for four genes, i.e., AKT1, DICER1, DROSHA, and COMT. Thus, the ΔCrt values of these four genes were decreased by treatment with risperidone in FEP patients with higher IL-6, but not in those with lower IL-6. There was additionally a significant effect of time on NDEL1 showing that the ΔCrt values were increased after treatment. The same table also shows the effects of treatment on the rating scale scores. All the psychopathological scale scores were significantly lowered by treatment with risperidone, while there was no significant interaction time × IL-6 groups.
Discussion
The first major finding of this investigation is that genes, which were associated with schizophrenia and/or bipolar disorder in previous studies, are significantly altered in blood of FEP patients. We found that NDEL1 and MBP genes were upregulated and DROSHA, COMT, and DISC1 were downregulated in FEP patients compared to controls. FEP patients also showed significantly increased serum levels of IL-10, IL-6, and TNF-α.
Interestingly, the NDEL1 and DISC1 were the most significant genes predicting FEP, and their combined use resulted in a significant diagnostic performance for FEP. NDEL1 encodes a protein involved in neuron outgrowth and migration, and cell signaling and is highly expressed in the brain [31]. A decrease in blood NDEL1 mRNA levels [32] and plasma NDEL1 enzyme activity [33] was reported in schizophrenia patients. In contrast to Kumarasinghe et al., who observed an upregulation of DISC1 in the schizophrenia patient group before and after antipsychotic treatment [34], we found a downregulation of this gene. DISC1 protein interacts with NDEL1, and this interaction mediates neurite outgrowth and neuronal migration [35–37]. The differences between our results and those in previous studies may be explained by differences in study sample selection, i.e., FEP patients versus schizophrenia patients in later stages and drug-free versus medicated patients.
The second major finding of this study is that FEP patients with depressive symptoms showed a different gene expression pattern compared to those without depressive symptoms. We found that FEP patients with more depressive symptoms (CDSS > 7) had an increased expression of COMT and decreased expression of NDEL1. Phrased differently, increased expression of NDEL1 and a lowered expression of COMT are hallmarks of FEP without depression. COMT is one of the enzymes responsible for the catabolism of dopamine in the brain, and the association between COMT Val158Met polymorphism and schizophrenia has been largely investigated [38]. Depression is a common and harmful dimension of schizophrenia, particularly in FEP [27, 39], and presents specific alterations in immune-inflammatory biomarkers [40, 41]. Recently, we have demonstrated that depression in FEP has a distinct cytokine profile, indicating that specific biological pathways may underpin this association [42]. Moreover, by investigating the co-expression of genes, Kim et al. (2015) observed a differential activation of the immune-inflammatory response across major psychiatric disorders, including schizophrenia and major depression [43]. Thus, the present results further underscore that FEP patients with depression are a biologically different phenotype than FEP patients without depression.
The third major finding of this study is that the circulating levels of cytokines, including IL-6, IL-10, and TNF-α, were significantly associated with the expression of several genes. As described in the Introduction, these cytokines modulate the expression of many different genes [44, 45]. We found that increased IL-6 was associated with lowered expression of AKT1 and DROSHA, while increased IL-10 was associated with increased NDEL1, DISC1, and MBP expression, all of them seem to play a role in neuronal processes and were significantly altered in FEP patients compared to controls. AKT1 signaling is involved in neuroplasticity and dopaminergic neurotransmission [46]. In addition, lithium, antidepressants, antipsychotics, and other mood stabilizers may increase phosphorylation of AKT1 [47–49]. Interestingly, there is also a connection between AKT1 and DISC1 signaling pathways [50]. DROSHA encodes a protein that is involved in the biogenesis of microRNA (miRNA), which is a short RNA with the capacity to target hundreds of genes, negatively regulating their expression in processes such as development and differentiation [51]. MBP is a component of the oligodendrocyte myelin and has a key role in myelin membrane biogenesis [52]. Genetic studies have described the involvement of myelin-related genes, including MBP, in schizophrenia [53, 54] and in FEP patients [55]. Thus, while increased IL-6 levels in FEP patients may downregulate cellular functions that are AKT1-mediated and dysregulate genes involved in miRNA machinery, increased IL-10 may show neuroprotective properties. Changes in the equilibrium between IL-6 and IL-10 production may therefore have consequences for neuronal functions. By inference, one possible pathway through which circulating cytokines may cause neuroprogression is regulation of the expression of genes related to neurogenesis, neuroplasticity, and neurodegeneration.
The fourth major finding is that treatment with risperidone has a significant effect on the expression of different genes, including AKT1, DROSHA, COMT, and NDEL1. Therefore, risperidone appears to normalize the initial disorders in gene expression by lowering NDEL1 and increasing COMT, DROSHA, and AKT1 expression. Most importantly, we found that the baseline circulating levels of IL-6 modulated the gene expression response of AKT1, DICER1, DROSHA, and COMT to treatment with risperidone. An upregulation of DICER1 was shown in the dorsolateral prefrontal cortex [56, 57] and lymphoblastoid cell lines [58] of schizophrenia cases. DICER1 is involved in the generation of miRNAs, similarly to DROSHA. Mutations in DICER1 abolish the generation of mature miRNAs and can induce deleterious developmental consequences, including malformations of the nervous system [59]. Thus, increased IL-6 levels appear to prime these genes to an enhanced response to risperidone, suggesting that cytokine × treatment interactions may improve cell function profiles (i.e., normalized DROSHA, COMT, and AKT1).
Our risperidone findings have important consequences for the interpretation of gene expression data in schizophrenia: (a) gene expression is only interpretable when fully controlled for the drug state of the patients and (b) baseline levels of circulating IL-6 should be taken into account for the interpretation of some gene expression data.
Conclusion
This study presents important data, shedding some light on gene expression in FEP and its interaction with depression and cytokine levels. We observed that gene expression and immune-inflammatory biomarkers are altered in FEP patients, as described previously. We also showed that FEP patients with depression present different expression of COMT and NDEL1 genes, strengthening the theory that distinct biological pathways underpin depression in FEP. Our results also suggest that circulating levels of IL-6 and IL-10 may regulate the expression of AKT1, DROSHA, NDEL1, DISC1, and MBP genes. We demonstrated that risperidone treatment may modulate gene expression and that these effects are partially regulated by cytokine levels, extending the comprehension of the role of the immune system in the pathophysiology of schizophrenia. The understanding of genetic and immune mechanisms in FEP opens new perspectives in the quest of biomarkers for the disorder and its treatment.
References
Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382(9904):1575–1586. doi:10.1016/S0140-6736(13)61611-6
Arnedo J, Svrakic DM, Del Val C, Romero-Zaliz R, Hernandez-Cuervo H, Molecular Genetics of Schizophrenia C, Fanous AH, Pato MT et al (2014) Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am J Psychiatry. doi:10.1176/appi.ajp.2014.14040435
Davis J, Moylan S, Harvey BH, Maes M, Berk M (2014) Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Austral N Z J Psychiatr 48(6):512–529. doi:10.1177/0004867414533012
Sullivan PF, Kendler KS, Neale MC (2003) Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 60(12):1187–1192. doi:10.1001/archpsyc.60.12.1187
Bodmer W, Bonilla C (2008) Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 40(6):695–701. doi:10.1038/ng.f.136
Schizophrenia Working Group of the Psychiatric Genomics C (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature 511(7510):421–427. doi:10.1038/nature13595
Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell’osso B, Kanba S, Monji A et al (2013) Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 42:1–4. doi:10.1016/j.pnpbp.2012.10.008
Ripke S, O’Dushlaine C, Chambert K, Moran JL, Kahler AK, Akterin S, Bergen SE, Collins AL et al (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet 45(10):1150–1159. doi:10.1038/ng.2742
Meyer U (2013) Developmental neuroinflammation and schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 42:20–34. doi:10.1016/j.pnpbp.2011.11.003
Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70(7):663–671. doi:10.1016/j.biopsych.2011.04.013
Park KM, Bowers WJ (2010) Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 22(7):977–983. doi:10.1016/j.cellsig.2010.01.010
Pan W, Zadina JE, Harlan RE, Weber JT, Banks WA, Kastin AJ (1997) Tumor necrosis factor-alpha: a neuromodulator in the CNS. Neurosci Biobehav Rev 21(5):603–613
Dunn AJ, Wang J, Ando T (1999) Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 461:117–127. doi:10.1007/978-0-585-37970-8_8
Thompson CD, Zurko JC, Hanna BF, Hellenbrand DJ, Hanna A (2013) The therapeutic role of interleukin-10 after spinal cord injury. J Neurotrauma 30(15):1311–1324. doi:10.1089/neu.2012.2651
Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R (2014) Brain-derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci 8:430. doi:10.3389/fncel.2014.00430
Song XQ, Lv LX, Li WQ, Hao YH, Zhao JP (2009) The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol Psychiatry 65(6):481–488. doi:10.1016/j.biopsych.2008.10.018
Mattson MP, Culmsee C, Yu Z, Camandola S (2000) Roles of nuclear factor kappaB in neuronal survival and plasticity. J Neurochem 74(2):443–456
Hodge DR, Xiao W, Clausen PA, Heidecker G, Szyf M, Farrar WL (2001) Interleukin-6 regulation of the human DNA methyltransferase (HDNMT) gene in human erythroleukemia cells. J Biol Chem 276(43):39508–39511. doi:10.1074/jbc.C100343200
Saradalekshmi KR, Neetha NV, Sathyan S, Nair IV, Nair CM, Banerjee M (2014) DNA methyl transferase (DNMT) gene polymorphisms could be a primary event in epigenetic susceptibility to schizophrenia. PLoS One 9(5):e98182. doi:10.1371/journal.pone.0098182
Wockner LF, Noble EP, Lawford BR, Young RM, Morris CP, Whitehall VL, Voisey J (2014) Genome-wide DNA methylation analysis of human brain tissue from schizophrenia patients. Translat Psychiatr 4:e339. doi:10.1038/tp.2013.111
Noto C, Ota VK, Gouvea ES, Rizzo LB, Spindola LM, Honda PH, Cordeiro Q, Belangero SI et al (2014) Effects of risperidone on cytokine profile in drug-naive first-episode psychosis. Int J Neuropsychopharmacol / Off Sci J Coll Int Neuropsychopharmacol 18 (4). doi:10.1093/ijnp/pyu042
Noto C, Ota VK, Gadelha A, Noto MN, Barbosa DS, Bonifacio KL, Nunes SO, Cordeiro Q et al (2015) Oxidative stress in drug naive first episode psychosis and antioxidant effects of risperidone. J Psychiatr Res 68:210–216. doi:10.1016/j.jpsychires.2015.07.003
Ota VK, Noto C, Gadelha A, Santoro ML, Ortiz BB, Andrade EH, Tasso BC, Spindola LM et al (2014) Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: a follow-up study in antipsychotic-naive patients with first-episode psychosis. J Psychiatr Res 56:130–136. doi:10.1016/j.jpsychires.2014.05.012
Ota VK, Noto C, Gadelha A, Santoro ML, Spindola LM, Gouvea ES, Stilhano RS, Ortiz BB et al (2014) Changes in gene expression and methylation in the blood of patients with first-episode psychosis. Schizophr Res. doi:10.1016/j.schres.2014.09.008
Ota VK, Noto C, Gadelha A, Santoro ML, Silva PN, Melaragno MI, Smith Mde A, Cordeiro Q et al (2013) Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naive first-episode psychosis patients before and after antipsychotic treatment. Psychiatry Res 210(3):1290–1292. doi:10.1016/j.psychres.2013.09.016
Gozdzik-Zelazny A, Borecki L, Pokorski M (2011) Depressive symptoms in schizophrenic patients. Europ J Med Res 16(12):549–552
Upthegrove R, Birchwood M, Ross K, Brunett K, McCollum R, Jones L (2010) The evolution of depression and suicidality in first episode psychosis. Acta Psychiatr Scand 122(3):211–218. doi:10.1111/j.1600-0447.2009.01506.x
Noto C, Gadelha A, Belangero SI, Spindola LM, Rocha NP, de Miranda AS, Teixeira AL, Cardoso Smith MA et al (2013) Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. J Psychiatr Res 47(4):467–471. doi:10.1016/j.jpsychires.2012.12.010
Vessoni AL (1993) Adaptação e estudo de confiabilidade da escala de avaliação das síndromes positiva e negativa para a esquizofrenia no Brasil. Escola Paulista de Medicina, São Paulo
Addington D, Addington J, Maticka-Tyndale E (1993) Assessing depression in schizophrenia: the Calgary Depression Scale. British J Psychiatr Suppl 22:39–44
Hayashi MA, Portaro FC, Tambourgi DV, Sucupira M, Yamane T, Fernandes BL, Ferro ES, Reboucas NA et al (2000) Molecular and immunochemical evidences demonstrate that endooligopeptidase A is the predominant cytosolic oligopeptidase of rabbit brain. Biochem Biophys Res Commun 269(1):7–13. doi:10.1006/bbrc.2000.2243
Rampino A, Walker RM, Torrance HS, Anderson SM, Fazio L, Di Giorgio A, Taurisano P, Gelao B et al (2014) Expression of DISC1-interactome members correlates with cognitive phenotypes related to schizophrenia. PLoS One 9(6):e99892. doi:10.1371/journal.pone.0099892
Gadelha A, Machado MF, Yonamine CM, Sato JR, Juliano MA, Oliveira V, Bressan RA, Hayashi MA (2013) Plasma Ndel1 enzyme activity is reduced in patients with schizophrenia—a potential biomarker? J Psychiatr Res 47(5):657–663. doi:10.1016/j.jpsychires.2013.01.009
Kumarasinghe N, Beveridge NJ, Gardiner E, Scott RJ, Yasawardene S, Perera A, Mendis J, Suriyakumara K et al (2013) Gene expression profiling in treatment-naive schizophrenia patients identifies abnormalities in biological pathways involving AKT1 that are corrected by antipsychotic medication. Int J Neuropsychopharmacol 16(7):1483–1503. doi:10.1017/S1461145713000035
Kamiya A, Tomoda T, Chang J, Takaki M, Zhan C, Morita M, Cascio MB, Elashvili S et al (2006) DISC1-NDEL1/NUDEL protein interaction, an essential component for neurite outgrowth, is modulated by genetic variations of DISC1. Hum Mol Genet 15(22):3313–3323. doi:10.1093/hmg/ddl407
Hayashi MA, Portaro FC, Bastos MF, Guerreiro JR, Oliveira V, Gorrao SS, Tambourgi DV, Sant’Anna OA et al (2005) Inhibition of NUDEL (nuclear distribution element-like)-oligopeptidase activity by disrupted-in-schizophrenia 1. Proc Natl Acad Sci U S A 102(10):3828–3833. doi:10.1073/pnas.0500330102
Hayashi MA, Guerreiro JR, Charych E, Kamiya A, Barbosa RL, Machado MF, Campeiro JD, Oliveira V et al (2010) Assessing the role of endooligopeptidase activity of Ndel1 (nuclear-distribution gene E homolog like-1) in neurite outgrowth. Mol Cell Neurosci 44(4):353–361. doi:10.1016/j.mcn.2010.04.006
Ira E, Zanoni M, Ruggeri M, Dazzan P, Tosato S (2013) COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation. J Psychiatr Neurosci : JPN 38(6):366–380. doi:10.1503/jpn.120178
Sonmez N, Rossberg JI, Evensen J, Barder HE, Haahr U, Ten Velden HW, Joa I, Johannessen JO et al (2014) Depressive symptoms in first-episode psychosis: a 10-year follow-up study. Early Interven Psychiatr. doi:10.1111/eip.12163
Talarowska M, Szemraj J, Berk M, Maes M, Galecki P (2015) Oxidant/antioxidant imbalance is an inherent feature of depression. BMC Psychiatr 15:71. doi:10.1186/s12888-015-0454-5
Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH (2015) IL-6, IL-18, sIL-2R, and TNFalpha proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord 182:106–114. doi:10.1016/j.jad.2015.04.044
Noto C, Ota VK, Santoro ML, Ortiz BB, Rizzo LB, Higuchi CH, Cordeiro Q, Belangero SI et al (2015) Effects of depression on the cytokine profile in drug naive first-episode psychosis. Schizophr Res. doi:10.1016/j.schres.2015.01.026
Kim S, Hwang Y, Webster MJ, Lee D (2015) Differential activation of immune/inflammatory response-related co-expression modules in the hippocampus across the major psychiatric disorders. Mol Psychiatry. doi:10.1038/mp.2015.79
Beveridge NJ, Cairns MJ (2012) MicroRNA dysregulation in schizophrenia. Neurobiol Dis 46(2):263–271. doi:10.1016/j.nbd.2011.12.029
Sun E, Shi Y (2014) MicroRNAs: small molecules with big roles in neurodevelopment and diseases. Exp Neurol. doi:10.1016/j.expneurol.2014.08.005
Balu DT, Coyle JT (2011) Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neurosci Biobehav Rev 35(3):848–870. doi:10.1016/j.neubiorev.2010.10.005
Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96(15):8745–8750
De Sarno P, Li X, Jope RS (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43(7):1158–1164
Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36(2):131–137. doi:10.1038/ng1296
Kim JY, Duan X, Liu CY, Jang MH, Guo JU, Pow-anpongkul N, Kang E, Song H et al (2009) DISC1 regulates new neuron development in the adult brain via modulation of AKT-mTOR signaling through KIAA1212. Neuron 63(6):761–773. doi:10.1016/j.neuron.2009.08.008
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P et al (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425(6956):415–419. doi:10.1038/nature01957
Aggarwal S, Yurlova L, Simons M (2011) Central nervous system myelin: structure, synthesis and assembly. Trends Cell Biol 21(10):585–593. doi:10.1016/j.tcb.2011.06.004
Matthews PR, Eastwood SL, Harrison PJ (2012) Reduced myelin basic protein and actin-related gene expression in visual cortex in schizophrenia. PLoS One 7(6):e38211. doi:10.1371/journal.pone.0038211
Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ et al (2003) Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362(9386):798–805. doi:10.1016/S0140-6736(03)14289-4
Santoro ML, Gadelha A, Ota VK, Cunha GR, Asevedo E, Noto CS, Spindola LM, Pan PM et al (2015) Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls. World J Biol Psychiatr:1–6. doi:10.3109/15622975.2015.1048724
Santarelli DM, Beveridge NJ, Tooney PA, Cairns MJ (2011) Upregulation of dicer and microRNA expression in the dorsolateral prefrontal cortex Brodmann area 46 in schizophrenia. Biol Psychiatry 69(2):180–187. doi:10.1016/j.biopsych.2010.09.030
Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ (2010) Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry 15(12):1176–1189. doi:10.1038/mp.2009.84
Sanders AR, Goring HH, Duan J, Drigalenko EI, Moy W, Freda J, He D, Shi J et al (2013) Transcriptome study of differential expression in schizophrenia. Hum Mol Genet 22(24):5001–5014. doi:10.1093/hmg/ddt350
Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, Baskerville S, Hammond SM, Bartel DP et al (2005) MicroRNAs regulate brain morphogenesis in zebrafish. Science 308(5723):833–838. doi:10.1126/science.1109020
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All participants provided written informed consent prior to enrollment in this study. The study was approved by the Research Ethics Committee of UNIFESP (Sao Paulo, Brazil) and carried out in accordance with the Declaration of Helsinki.
Conflict of Interest
Dr. Noto has received a scholarship from Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). Dr. Gadelha was on the speakers’ bureau and/or has acted as a consultant for Janssen-Cilag in the last 12 months and has also received research support from Brazilian government institutions (CNPq). Dr. Bressan has received research funding from FAPESP, CNPq, CAPES, Fundação Safra, Fundação ABADS, Janssen, Eli Lilly, Lundbeck, Novartis and Roche, has served as a speaker for Astra Zeneca, Bristol, Janssen, Lundbeck and Revista Brasileira de Psiquiatria, and is a shareholder of Radiopharmacus Ltda and Biomolecular Technology Ltda. Dr. Maes is supported by CNPq (Conselho Nacional de Desenvolvimento Cientifico e Technologia) PVE fellowship at the Health Sciences Graduate Program, Londrina State University (UEL). The other authors have no conflicts of interest to disclose.
Role of Funding Source
Funding for this study was provided by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, 2010/08968-6, 2010/19176-3, 2011/50740-5 and 2013/10498-6), Brazil.x
Additional information
Cristiano Noto and Vanessa Kiyomi Ota contributed equally to this work.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 68 kb)
Rights and permissions
About this article
Cite this article
Noto, C., Ota, V.K., Santoro, M.L. et al. Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis. Mol Neurobiol 53, 5701–5709 (2016). https://doi.org/10.1007/s12035-015-9489-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-015-9489-3